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Introduction: Use of maintenance bronchodilator therapy is currently recom-
mended in symptomatic patients with Chronic obstructive pulmonary disease (COPD)
and in those with Stage II or greater COPD as defined by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD). Because no prospective data describe
when rescue therapy alone is insufficient or the optimal time to start maintenance
therapy, it is unclear whether maintenance therapy has benefits in milder disease. To
explore potential benefits we asked: Does once-daily tiotropium improve lung
function, health status, and/or symptoms in ‘‘undertreated’’ COPD patients (i.e.,
those who are not receiving maintenance bronchodilator therapy) or patients
considered by their health care providers as having milder disease?
Methods: A post-hoc analysis of data from COPD patients participating in two, 1-
year, placebo-controlled trials with tiotropium was performed. Patients were
defined as ‘‘undertreated’’ if they received no respiratory medication or only as-
needed short-acting b-agonists prior to enrollment. Measures included serial
spirometry, Transition Dyspnea Index (TDI), and St. George’s Respiratory Ques-
tionnaire (SGRQ).
Results: Of 921 patients enrolled, 218 (23.7%) were ‘‘undertreated’’: 130 received
tiotropium; 88 received placebo. Demographics for the two treatment groups were
comparable. Tiotropium-treated patients had significantly improved forced expira-
tory volume in 1 s (FEV1) and forced vital capacity (FVC) compared with patientsElsevier Ltd. All rights reserved.
7 5256; fax: +210 949 3006.
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S.G. Adams et al.1496using placebo on all study days. Additionally, TDI and SGRQ scores significantly
improved with tiotropium compared with placebo.
Conclusions: Once-daily tiotropium provides significant improvement in lung
function, health status, and dyspnea when used as maintenance therapy in
undertreated COPD patients who were not previously receiving maintenance
bronchodilator therapy.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
disease that affects millions of people worldwide,
is currently ranked as the fifth leading cause of
death globally, and incurs significant health care
expenditures.1–6 Recently, focus has been drawn to
COPD as a public health issue through efforts such
as the Global Initiative for Chronic Obstructive Lung
Disease (GOLD), and organizations such as the
American Thoracic Society (ATS) and European
Respiratory Society (ERS), which have published
recommendations to help optimize COPD diagnosis
and management.3,7
COPD begins with an asymptomatic phase in
which lung function deteriorates without asso-
ciated symptoms. The onset of the subsequent
symptomatic phase is variable, but often does not
occur until the forced expiratory volume in 1 s
(FEV1) has fallen to approximately 50% of the
predicted normal value.8 Airflow obstruction is
generally progressive over a period of years and is
only partially reversible.9,10 Bronchodilators are
important treatments to reduce symptoms in COPD.
However, the optimal timing and the specific
criteria (based on respiratory symptoms versus
FEV1) for initiating maintenance (i.e., regularly
scheduled) bronchodilator therapy have not been
addressed or clearly defined by clinical trials.
Guidelines for COPD management suggest that
maintenance therapy is indicated for those patients
with at least moderate disease (GOLD Stage II or
higher) or patients that are symptomatic.3,7 How-
ever, in clinical practice many patients (up to 45%)
who have visits to a healthcare professional with
the diagnosis of COPD have not ever had spirometry
performed.11 Since healthcare professionals usually
prescribe maintenance bronchodilators for COPD
patients after an acute exacerbation of COPD or as
a result of significant respiratory symptoms, one
functional definition of ‘‘undertreated’’ disease
may include patients who are not prescribed
maintenance bronchodilator therapy.
To address whether once-daily tiotropium im-
proves lung function, health status, and/or symp-
toms in undertreated COPD patients, we pooled thedata from two large, 1-year, placebo-controlled
studies of inhaled tiotropium 18 mg conducted in
the United States.12 We evaluated the efficacy of
once-daily tiotropium 18 mg given as a first-line
maintenance therapy to patients with ‘‘under-
treated’’ COPD. We defined subjects as having
‘‘undertreated’’ disease if they had previously
received either no respiratory medications or only
as-needed short-acting b-agonists. Additionally, we
examined the effects of tiotropium 18 mg in two
other subsets of subjects: (1) in the ‘‘under-
treated’’ group according to baseline post-bronch-
odilator FEV1o50% orX50% predicted, and (2) in a
non-unique subset of subjects in the 1-year studies
who were classified as having GOLD Stage I ‘‘mild’’
COPD by post-bronchodilator FEV1 at day 8 (re-
ferred to as ‘‘mild by GOLD staging’’).3Methods
Study subjects
A post hoc analysis was performed on data from two
identical, 1-year, randomized, double-blind, place-
bo-controlled, parallel-group studies of once-daily
inhaled tiotropium 18 mg in patients with COPD
(trials 205.117 and 205.128).12 Fifty clinical centers
participated in these trials and each center’s
institutional review board approved the protocol.
All subjects provided written informed consent
prior to participation.
The study groups consisted of outpatients of
either gender who were at least 40 years of age
with a clinical diagnosis of COPD, as defined by the
ATS.9 Participants were required to have at least a
10-pack-year history of smoking, clinically stable
airway obstruction, an FEV1 less than 70% of the
forced vital capacity (FVC) and an FEV1 of less than
65% of the predicted normal value.13 Subjects were
excluded if they had a history of asthma, allergic
rhinitis, atopy, or a total blood eosinophil count of
more than 600/mm3. Subjects were excluded if
they required regular daytime supplemental oxy-
gen, were on corticosteroid doses exceeding the
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month prior to entering the study, had a recent
history of myocardial infarction (1 year or less),
hospitalization for heart failure (3 years or less),
cardiac arrhythmias requiring drug therapy, symp-
tomatic prostatic hypertrophy, or narrow angle
glaucoma.Study design
Following a 2-week baseline period, subjects were
randomly assigned to receive either tiotropium
(18 mg) or placebo. Subjects were randomized in
3:2 tiotropium:placebo ratios. Subjects were ad-
ministered active medication (tiotropium in lac-
tose) or placebo (lactose) by inhalation, one dose
each morning in identical-appearing capsules via a
dry-powder inhaler device (HandiHalers, Boehrin-
ger Ingelheim GmbH & Co. KG, Ingelheim, Ger-
many).14 Subjects were permitted to use an
albuterol metered-dose inhaler, as needed,
throughout the study. No other inhaled antic-
holinergics (other than study drug) or b-agonists
(long-acting inhaled or oral) were allowed during
the study. Investigators were permitted to pre-
scribe any therapy that was medically necessary,
including antibiotics and systemic corticosteroids,
to treat acute exacerbations of COPD during the
trial.
Spirometric testing was conducted according to
ATS standards on treatment day 1 (baseline), on
day 8, and at 6, 12, 24, 36, and 48 weeks of
treatment.15 Drugs were to be administered at the
same time each day (between 7 and 9 am). On test
days, FEV1 and FVC were measured and recorded at
1 h and at 5min prior to dosing study medication
and at 30, 60, 120 and 180min post-dose. Trough
values of FEV1 and FVC were calculated as the
mean of the two pre-dose measurements, i.e.,
approximately 23 and 24 h after the previous dose
of study medication. The changes in lung function
over time were evaluated by examining trough and
peak FEV1 and FVC from day 8 to day 344. As
previously noted, a subgroup of subjects was
defined as having ‘‘undertreated’’ disease if they
had previously received either no respiratory
medications or only as-needed short-acting
b-agonists. An additional subset of (non-unique)
subjects whose FEV1 improved to greater than 80%
of the predicted normal value on day 8, were
analyzed and are referred to in this manuscript as
‘‘mild by GOLD staging.’’ As GOLD indicates that
FEV1 staging should be based on post-bronchodila-
tor values and acute responses to short-acting
bronchodilators was not assessed in the clinicaltrials, we used the post-tiotropium value on day 8
as a surrogate. Other than at day 8, the Transition
Dyspnea Index (TDI) and the St. George’s Respira-
tory Questionnaire (SGRQ) were measured on the
same days as the spirometry measurements.
Analysis
Data are presented as proportions or means
(standard deviation or standard error). Data were
analyzed using analysis of covariance (ANCOVA) at
each visit to compare the change in response over
the year in the two treatment groups of the
‘‘undertreated’’ COPD patients. The consistency
of effects across subgroups based on severity or
smoking status was assessed by testing treatment-
by-subgroup interaction effects. For patients dis-
continued due to worsening of their disease (5% of
patients), missing data were imputed using the
least favorable data. For those who discontinued
for other reasons, their missing data were imputed
by carrying the last observation forward. A TDI
Focal score of at least one unit was considered a
clinically significant change in activity-related
dyspnea.16–18 A change in SGRQ score of at least 4
units was considered to be a clinically significant
change in quality of life.19 Statistical significance
was considered at Po0:05.Results
Of 921 subjects enrolled in these two clinical trials,
we identified a group of 218 (23.7%) subjects who
were ‘‘undertreated,’’ defined as those who were
not receiving maintenance respiratory medications
(i.e., either no respiratory medications (N ¼ 178)
or only short-acting b-agonists (N ¼ 40) upon
entry). Within this subgroup of ‘‘undertreated’’
subjects, 130 received tiotropium and 88 received
placebo. The subject characteristics at baseline
were similar between groups (Table 1). The mean
age was 64 years, they were predominantly male,
smoked an average of 62 pack-years, and had a
mean FEV1 of 1.13 L (Table 1). Approximately 26%
of placebo treated subjects and 19% of tiotropium
treated subjects prematurely discontinued partici-
pation in the trial. The reasons for discontinuation
are listed in Table 2.
Spirometry
The mean changes from baseline in trough FEV1 and
FVC over 1 year of treatment in this ‘‘under-
treated’’ subgroup are shown in Figs. 1 and 2. These
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Table 1 Baseline patient characteristics in the
‘‘undertreated’’ subgroup of those receiving tio-
tropium and placebo.
Characteristic Tiotropium Placebo
Number 130 88
Age (years) 62.8 (8.9) 64.7 (9.5)
Males (%) 62.3 55.7
Duration of COPD
(years)
7.6 (6.7) 6.1 (5.6)
Smoking history
(pack-years)
65.1 (31.1) 58.5 (29.9)
Current smokers (%) 49.2 47.7
Screening spirometry
FEV1 (L) 1.18 (0.47) 1.05 (0.44)
y
FEV1 (% predicted) 41.6 (13.8) 39.2 (14.5)
FVC (L) 2.39 (0.83) 2.26 (0.83)
FEV1/FVC (%) 50.0 (11.1) 47.3 (12.3)
FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced
vital capacity.
Data presented as mean (SD) or proportions.
yPo0:05.
Table 2 Reasons for premature discontinuation in
the placebo and tiotropium groups.
Reasons Tiotropium Placebo
Total discontinuations 25 (19.2) 23 (26.1)
Adverse
event—worsening of
COPD
1 (0.8) 4 (4.6)
Adverse
event—worsening of
pre-existing disease
(not COPD)
1 (0.8) 1 (1.1)
Adverse event—other 5 (3.9) 8 (9.1)
Consent withdrawn 8 (6.2) 2 (2.3)
Lack of efficacy 2 (1.5) 5 (5.7)
Lost to follow-up 4 (3.1) 2 (2.3)
Other 4 (3.1) 1 (1.1)
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Figure 1 Mean difference (Standard Error (SE)) from
baseline in trough and peak FEV1 response in the
‘‘undertreated’’ tiotropium group and placebo group
between day 8 and day 344. (A) Trough FEV1 response,
and (B) peak FEV1 response. *Po0:001 vs. placebo.
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Figure 2 Mean difference (SE) from baseline in trough
and peak FVC response in the ‘‘undertreated’’ tiotropium
group and placebo group between day 8 and day 344. (A)
Trough FVC response, and (B) peak FVC response.
S.G. Adams et al.1498subjects who were treated with tiotropium had
significantly higher mean trough FEV1 and FVC
and peak FEV1 and FVC on all study days compared
with those who received placebo (Po0:001 in all
cases). At the end of the study, the mean trough
FEV1 was 190mL greater and the mean FVC was
400mL greater for the tiotropium treated subgroup
than for the placebo group. In addition, the
magnitude of difference in mean peak FVC was
540mL larger in the ‘‘undertreated’’ subjects
treated with tiotropium than those treated with
placebo.*Po0:001 vs. placebo.
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Figure 4 Mean difference from baseline in St. George’s
Respiratory Questionnaire (SGRQ) Total scores over 1 year
in the tiotropium ‘‘undertreated’’ group and the placebo
group. *Po0.05 vs. placebo.
Tiotropium in COPD patients without maintenance therapy 1499Dyspnea
Dyspnea assessed by the TDI Focal score for this
‘‘undertreated’’ subgroup improved 0.89 in the
tiotropium treated group compared with placebo
by the end of the year (Po0:05) (Fig. 3). Upon
further analysis, the differences in TDI Focal scores
between tiotropium and placebo in the subgroup of
active smokers within the ‘‘undertreated’’ subject
group improved more than in the former smokers
(active smokers [tiotropium N ¼ 54, placebo
N ¼ 37] improved 1.14 and former smokers [tio-
tropium N ¼ 59, placebo N ¼ 39] improved 0.65);
however, the difference between active vs. former
smokers was not statistically significant (P ¼ 0:5).
Health status
Heath status as assessed by the SGRQ Total score
improved 5.2 units in the tiotropium treated
subjects compared with placebo at the end of
therapy in this ‘‘undertreated’’ subgroup (Po0:05)
(Fig. 4). At the end of the study, the differences
from baseline for SGRQ Activity, Impact, and Total
scores improved significantly more in subjects who
received tiotropium than in those who received
placebo. The mean Symptom scores improved by
5.1 in the tiotropium group over the placebo;
however, this difference was not statistically
significant (P ¼ 0:07). In addition, the differences
in the SGRQ scores between the tiotropium and
placebo groups were not different between those
who were active vs. former smokers.
Use of rescue medication
In this ‘‘undertreated’’ group, the mean use of as-
needed albuterol (2.6 doses/day at baseline) was0.0
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Figure 3 Mean transition dyspnea index (TDI) Focal
scores over 1 year in the tiotropium ‘‘undertreated’’
group and the placebo group. *Po0.05 vs. placebo.reduced by 0.6 doses/day with tiotropium and was
increased by 0.4 doses/day with placebo
(P ¼ 0:0007).Analyses of other subsets of subjects
An analysis of the subset of ‘‘undertreated’’
subjects with a baseline FEV1o50% predicted
(tiotropium N ¼ 84, placebo N ¼ 55) compared
with those with a baseline FEV1X50% predicted
(tiotropium N ¼ 35; placebo N ¼ 23) demonstrated
that trough and peak FEV1 and FVC significantly
improved at all measured study days after day 50
with tiotropium vs. placebo in the subgroup with
the lower lung function. The differences in lung
function at day 344 between the tiotropium and the
placebo groups are shown in Table 3 for these
subgroups of patients based on their baseline FEV1
values. In addition, the differences in TDI Focal
scores between tiotropium and placebo signifi-
cantly improved in the subset of subjects with the
lower lung function (FEV1o50% predicted, tiotro-
pium N ¼ 79, placebo N ¼ 53) compared with those
with higher lung function (FEV1X50% predicted,
tiotropium N ¼ 34, placebo N ¼ 23) (1.32 vs.
0.12, respectively, P ¼ 0:07). Finally, the subjects
with very low FEV1(o50% predicted) demonstrated
the most significant improvement in mean SGRQ
total scores at each of the study days (7.48 on day
344 for the subgroup with FEV1o50% predicted vs.
0.15 for the subgroup with FEV1X50% predicted
Po0:05).
We analyzed another subset of 20 non-unique
subjects with GOLD Stage I (Mild) disease by
spirometry on day 8 (all from the tiotropium-
treated group). Twelve of the 20 subjects in this
‘‘mild disease by GOLD staging’’ subset were also in
the ‘‘undertreated’’ subgroup. The characteristics
ARTICLE IN PRESS
Table 3 Subgroup analysis of differences (tiotropium—placebo) in lung function in the ‘‘undertreated’’
subgroup at day 344 based on severity of baseline lung function (FEV1).

Differences in lung function at day 344 (tiotropium vs. placebo)
FEV1o50% predicted
tiotropium (N ¼ 84)
placebo (N ¼ 55)
P-value FEV1X50% Predicted
tiotropium (N ¼ 35)
placebo (N ¼ 23)
P-value
Trough (predose)
FEV1 (mL)
252 (43) o0.0001 41 (66) 0.539
Peak FEV1 (mL) 317 (45) o0.0001 123 (70) 0.082
Average FEV1 (mL) 305 (43) o0.0001 98 (67) 0.141
Trough (predose)
FVC (mL)
507 (74) o0.0001 143 (115) 0.217
Peak FVC (mL) 661 (77) o0.0001 252 (119) 0.035
Average FVC (mL) 609 (75) o0.0001 266 (117) 0.024
FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity.
Data presented as mean (SE).
Table 4 Baseline characteristics of the subset of
COPD subjects with ‘‘mild disease by GOLD
staging’’ at day 8 (all subjects were in the
tiotropium treated group).
Characteristic Tiotropium
Number 20
Age (years) 69 (11)
Males (%) 70
Smoking history (pack-years) 70 (35)
Duration of COPD (years) 11.3 (9.9)
FEV1 (L) 1.68 (0.55)
FEV1 (% predicted) 62 (8)
FVC (L) 3.05 (1.00)
FEV1/FVC (%) 55 (7)
FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced
vital capacity.
Data presented as mean (SD) or proportions.
S.G. Adams et al.1500of this subset of 20 subjects with ‘‘mild disease by
GOLD staging’’ are listed in Table 4. The trough,
peak, and mean values for FEV1 and FVC signifi-
cantly improved from baseline on all study days in
this ‘‘mild disease by GOLD staging’’ subset who all
received tiotropium. At the end of the study, the
mean (SE) percent improvements from baseline in
trough (predose), peak and average FEV1 were 15.4
(4.8), 26.0 (5.9) and 21.6 (5.2), respectively, and
results for FVC were 7.6 (4.7), 18.7 (5.5) and 13.4
(4.9), respectively, showing that improvements in
lung function were seen irrespective of ‘‘mild’’
severity and persisted over a period of 23–24 h after
dosing. In addition, this subset of subjects had
marked improvements in their SGRQ Total score
(mean-6.1 units) at the end of the study (Day 344).Finally, the mean use of as-needed albuterol with
tiotropium (2.9 doses/day at baseline) was reduced
by an average of 0.7 doses/day in this subset of
subjects with ‘‘mild disease by GOLD staging.’’Discussion
The present post hoc analysis of two 1-year,
placebo-controlled trials suggests that tiotropium
18 mg once daily provides significant improvement
in lung function, dyspnea, and health status when
used by ‘‘undertreated’’ COPD subjects, defined
clinically as those not previously receiving main-
tenance inhaler therapy. The subset of ‘‘under-
treated’’ subjects with the lowest lung function
(baseline FEV1o50% predicted) demonstrated the
largest improvement in these outcomes. However,
the subjects with severe obstruction to airflow
were not the only subjects to benefit from
tiotropium: the subset of non-unique subjects with
‘‘mild disease by GOLD staging’’ who were treated
with tiotropium also demonstrated significant im-
provements in lung function and health status.
The observed differences from placebo within
the ‘‘undertreated’’ subset of subjects with COPD
were similar to or greater than those seen in the
entire cohort.12 The absolute differences from
placebo in the mean trough FEV1 and FVC in the
‘‘undertreated’’ subgroup of subjects were larger
than those seen in the full cohort (mean trough
FEV1 ¼ 190mL in the subgroup vs. 150mL in the
whole cohort, and mean trough FVC ¼ 400mL vs.
290mL, respectively).12 The magnitude of differ-
ence from placebo in mean peak FVC was also
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full cohort (540mL vs. 440mL). The improvement
of the tiotropium group above the placebo group in
the TDI Total score was similar for the ‘‘under-
treated’’ subgroup and the full cohort (0.89 vs.
1.14, respectively). In addition, the improvement
in SGRQ total score was greater in the ‘‘under-
treated’’ subgroup than in the entire cohort (5.2
vs. 3.7, respectively).12 Bronchodilators are
usually prescribed to relieve symptoms, reverse
airway obstruction and to improve the overall
morbidity associated with COPD.3,9,10 As-needed
short-acting b-agonists are currently recommended
for the rapid relief of respiratory symptoms
associated with COPD.3,7 The guidelines and cur-
rent recommendations suggest however, that if
short-acting bronchodilators do not control symp-
toms adequately, a long-acting bronchodilator can
be added or substituted, but there are minimal
data regarding the optimal timing of initiating
maintenance therapy.3,7,20 For the ‘‘undertreated’’
subgroup of subjects with COPD described in this
study, the absence of maintenance therapy could
potentially indicate that their health care providers
either considered these patients as having mild
disease or were unaware of the options for
maintenance airway medication.
COPD is frequently not recognized until the
clinically advanced stages of the disease. Zaas
et al.21 reported data from spirometry and ques-
tionnaires performed in 153 patients admitted to a
general medicine service for any medical problems
during a 7-month period in 2000. Fewer than 5%
were admitted with either an asthma or COPD
exacerbation. Overall, 26% had evidence of ob-
struction by spirometry; whereas, only 9% had the
diagnosis of an obstructive lung disease at admis-
sion. At hospital discharge, 67–70% of patients with
moderate to severe airway obstruction by spiro-
metry were not diagnosed with COPD prior to, or
during, their hospital stay and only 40% of these
patients received bronchodilators at hospital ad-
mission and/or discharge.21 Surprisingly, 11% of the
patients with very severe airway obstruction
(FEV1o30% predicted) did not have the diagnosis
of COPD at discharge. Furthermore, there is a
potential problem with relying on patients devel-
oping symptoms prior to initiating scheduled,
maintenance bronchodilator therapy because pa-
tients with COPD often do not report symptoms to
physicians until they have significantly reduced
lung function. Depending on the population studied
(routine screening of smokers vs. inpatients pre-
senting with first episode of acute exacerbation of
COPD), between 10% and 60% of newly diagnosed
COPD patients have an FEV1 percent predicted of50% or less.22–24 This current study supports the
guideline recommendations to begin scheduled
bronchodilator therapy for COPD patients with
GOLD Stages II or higher (moderate to very severe).
However, regularly scheduled bronchodilator ther-
apy may be beneficial even in the patients who are
not complaining of respiratory symptoms. Although
the specific mechanism for the fact that the largest
benefit in lung function with tiotropium is in the
subgroup of ‘‘undertreated’’ COPD subjects with
lower baseline lung function is unclear, one can
speculate that utilizing a bronchodilator with a 24-
h duration of action improves patient adherence
and reduces hyperinflation throughout the day and
night, which may influence long-term changes in
spirometry, health status, and acute exacerba-
tions.25,26
Our data support the need to identify patients
with COPD early in the course of their disease. The
consensus statement from the National Lung Health
Education Program recommends the widespread
use of spirometry for patients older than 45 years
who have significant cigarette smoke exposure.27
Several investigators have demonstrated that
spirometry is able to identify patients with COPD,
who were not detected using a symptom related
screening questionnaire.23 Although there is con-
troversy in the literature regarding the value of
screening spirometry, the guidelines clearly state
that spirometry is required to diagnose and stage
patients with COPD.3,7,28
There are several limitations to our study. We
performed a retrospective, post hoc analysis of
data collected prospectively from two clinical trials
that were conducted in a rigorous fashion, but were
not specifically designed to assess differences in
lung function, dyspnea, rescue b-agonist use, or
health status in the subgroups of COPD patients
analyzed in the present report. Other data that are
important in this patient population, such as type
and duration of symptoms and access to health
care, were not collected. Prospective epidemiolo-
gic studies have suggested that patients with
respiratory symptoms are very likely to avoid
medical treatment, which is why most of these
patients are not identified until the advanced
stages of the disease.29 In the present analysis,
the tiotropium and placebo treated patients had
similar baseline characteristics including a similar
percent predicted FEV1, although the absolute
(i.e., mL) FEV1 was statistically different which
likely reflects a minor difference in gender dis-
tribution between groups. In addition, limiting
the analyses to the ‘‘undertreated’’ and/or ‘‘mild
by GOLD staging’’ subset results in a smaller
sample size that may have inadequate power.
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placebo arm may have also biased the results.
However, one can argue that the more severely ill
patients were not able to complete the study
period and, as a consequence, the results may
underestimate the tiotropium effect.
Conclusions
This study (1) demonstrates that tiotropium 18 mg
once daily provides significant improvement in lung
function, dyspnea, and health status when given to
COPD subjects who previously received either no
respiratory medications or only as-needed short-
acting b-agonists and (2) supports the hypothesis
that tiotropium should be used as a first-line
maintenance therapy in COPD patients. Not surpris-
ingly, the subgroup within this ‘‘undertreated’’
COPD population who appears to benefit the most
from scheduled therapy with tiotropium is the
group with very low lung function (FEV1o50%
predicted). Nevertheless, we also identified sig-
nificant clinical benefits in lung function and health
status in a subset of subjects with a post-bronch-
odilator FEV1480% predicted (i.e., GOLD mild
disease). The present study indicates that health
care providers need to be vigilant in their assess-
ment of patients with COPD to insure that patients
are receiving maintenance bronchodilators based
on a consideration of symptoms and objective
measures of airflow limitation. Future studies
designed to identify the optimal time to initiate
scheduled, maintenance therapy to potentially
modify the clinical course for patients with COPD
are indicated, particularly since some of the
patients with FEV1o50% predicted may have
minimal to no respiratory symptoms at presenta-
tion and others may be symptomatic with mild
airflow limitation.Acknowledgments
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